MINOXIDIL (FOR MEN)
Clinical safety rating: safe
Other antihypertensive drugs can have additive effects Can cause pericardial effusion and hypertrichosis.
Minoxidil is a direct-acting peripheral vasodilator that opens ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation. In hair follicles, it promotes hair growth by increasing blood flow, stimulating prostaglandin synthesis, and prolonging the anagen phase.
| Metabolism | Minoxidil is primarily metabolized in the liver via conjugation with glucuronic acid to form minoxidil glucuronide. Enzymes involved include UDP-glucuronosyltransferases (UGTs). |
| Excretion | Renal: 85-90% (primarily unchanged drug and metabolites). Biliary/fecal: <5%. |
| Half-life | Terminal half-life: 3.5-4.5 hours. Clinical context: Short half-life necessitates twice-daily dosing for hypertension; for topical use, systemic absorption is minimal so half-life less relevant. |
| Protein binding | 20-25% bound to plasma proteins (albumin). |
| Volume of Distribution | Vd: 2-3 L/kg. Clinical meaning: Extensive extravascular distribution, high tissue penetration. |
| Bioavailability | Oral: 90-95% (rapidly absorbed). Topical: <1.4% (minimal systemic absorption from 5% solution). |
| Onset of Action | Oral: 30 minutes (hypotensive effect). Topical: 2-4 months for visible hair regrowth. |
| Duration of Action | Oral: 4-6 hours (antihypertensive effect). Topical: Continuous use required to maintain hair growth; discontinuation leads to reversal within 3-4 months. |
Oral: 2.5-5 mg once daily; may increase to 10 mg once daily if needed. Topical: 5% solution, 1 mL applied to dry scalp twice daily; 5% foam, half a capful applied twice daily; 2% solution, 1 mL applied twice daily.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dosage adjustment required for GFR >10 mL/min; for GFR <10 mL/min, reduce dose by 50% or extend interval to every 48 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: initiate at 2.5 mg once daily; Child-Pugh Class C: avoid use or use with caution; no specific guidelines available. |
| Pediatric use | Not approved for use in pediatric patients for hypertension; for topical use in alopecia, not established in children <18 years. |
| Geriatric use | Initiate at lowest dose (2.5 mg orally once daily) and titrate slowly; monitor for orthostatic hypotension, dizziness, and edema due to increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other antihypertensive drugs can have additive effects Can cause pericardial effusion and hypertrichosis.
| FDA category | Animal |
| Breastfeeding | Minoxidil is excreted in breast milk. M/P ratio not established. Potential for adverse effects (e.g., hypotension, hypertrichosis) in nursing infants. Contraindicated during breastfeeding. |
| Teratogenic Risk | Minoxidil is contraindicated in pregnancy (FDA Category C). Animal studies show fetal abnormalities (ossification delays, reduced fetal weight) at high doses. First trimester: Potential for teratogenicity based on animal data; human data insufficient. Second and third trimesters: Risk of fetal hypotension and hypertrichosis; avoid use. |
■ FDA Black Box Warning
None.
| Common Effects | androgenetic alopecia |
| Serious Effects |
["Hypersensitivity to minoxidil or any component of the formulation","Application to broken, irritated, or sunburned scalp","Concomitant use with other topical agents on the scalp"]
| Precautions | ["May cause severe hypertrichosis (excessive hair growth) on face and extremities","Risk of systemic absorption leading to cardiovascular effects like tachycardia and fluid retention, especially with excessive application","Avoid contact with eyes and mucous membranes","Discontinue if chest pain, rapid heartbeat, faintness, or dizziness occurs","Use caution in patients with cardiovascular disease or hypertension"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of fluid retention (weight gain, edema). Fetal monitoring: Assess for growth restriction by ultrasound; monitor fetal heart rate for bradycardia or arrhythmia if maternal use occurs. |
| Fertility Effects | No known adverse effects on male or female fertility. In animal studies, no impairment of fertility was observed at clinically relevant doses. |